Resultats globals: 7 registres trobats en 0.02 segons.
Articles, 7 registres trobats
Articles 7 registres trobats  
1.
12 p, 926.4 KB Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines / García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Saiz-Rodríguez, M. (Hospital Universitario de Burgos) ; Mondéjar, R. (Hospital Universitario de la Princesa (Madrid)) ; Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Borobia, A. M. (Hospital Universitario La Paz (Madrid)) ; Safont, M. J. (Universitat de València) ; García-García, I. (Hospital Universitario La Paz (Madrid)) ; Colomer, R. (Hospital Universitario de la Princesa (Madrid)) ; García-González, X. (Hospital General Universitario Gregorio Marañón) ; Herrero, M. J. (Universitat de València) ; López-Fernández, L. A. (Hospital General Universitario Gregorio Marañón) ; Abad-Santos, F. (Hospital Universitario de la Princesa (Madrid)) ; Universitat Autònoma de Barcelona
5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. [...]
2021 - 10.1007/s12094-021-02708-4
Clinical & Translational Oncology, Vol. 24 (november 2021) , p. 483-494  
2.
9 p, 1.6 MB Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine (Madrid)) ; Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; García-Carbonero, Rocío (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; G-Pastrián, Laura (Hospital Universitario La Paz (Madrid)) ; Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ; Peña, Cristina (Hospital Universitario La Paz (Madrid)) ; López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco) ; Llorens, Carlos (Biotechvana SL (Madrid)) ; Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ; Conill, Carles (Hospital Clínic i Provincial de Barcelona) ; Heredia-Soto, Victoria (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Fresno Vara, Juan Ángel (Centro de Investigación Biomédica en Red de Cáncer) ; Feliu, Jaime (Universidad Autónoma de Madrid) ; Universitat Autònoma de Barcelona
Squamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80-90% of tumors). [...]
2021 - 10.1038/s41598-021-86966-w
Scientific reports (Nature Publishing Group), Vol. 11 (april 2021)  
3.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
4.
16 p, 1003.6 KB Update of the recommendations for the determination of biomarkers in colorectal carcinoma : National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology / García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; García-Foncillas, Jesús (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Pérez-Segura, Pedro (Hospital Clínico San Carlos (Madrid)) ; Salazar, R. (Centro de Investigación Biomédica en Red de Cáncer) ; Vera, Ruth (Complejo Hospitalario de Navarra) ; Ramón y Cajal, S. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hernández-Losa, J. (Hospital Universitari Vall d'Hebron) ; Landolfi, S. (Vall d'Hebron Institut d'Oncologia) ; Musulén, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; Navarro, S. (Hospital Clínic Universitari (València)) ; Universitat Autònoma de Barcelona
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica-SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica-SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. [...]
2020 - 10.1007/s12094-020-02357-z
Clinical & Translational Oncology, Vol. 22 (may 2020) , p. 1976-1991  
5.
8 p, 712.6 KB Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study / Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ; Portnoy, D C (The West Clinic, Memphis, USA) ; Obermannová, R (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ; Bodoky, G (St László Hospital (Hongria)) ; Prausová, J (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Ciuleanu, T (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Cohn, A L (Rocky Mountain Cancer Center, LLP, Denver, USA) ; Van Cutsem, E (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Yamazaki, K (Shizuoka Cancer Center, Shizuoka, Japan) ; Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ; Muro, K (Aichi Cancer Center Hospital) ; Kim, T W (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ; Yamaguchi, K (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ; Grothey, A (Mayo Clinic, Phoenix, USA) ; O'Connor, J (Instituto Alexander Fleming (Buenos Aires, Argentina)) ; Taieb, J (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ; Wijayawardana, S R (Eli Lilly and Company, Indianapolis, USA) ; Hozak, R R (Eli Lilly and Company, Indianapolis, USA) ; Nasroulah, F (Eli Lilly and Company, Buenos Aires, Argentina) ; Tabernero, J (Universitat Autònoma de Barcelona. Departament de Medicina) ; Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131  
6.
8 p, 1.4 MB Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma / Trilla-Fuertes, Lucía (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; Ghanem, Ismael (Hospital Universitario La Paz (Madrid)) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; G-Pastrián, Laura (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Mendiola, Marta (Centro de Investigación Biomédica en Red de Cáncer) ; Peña, Cristina (Hospital Universitario La Paz (Madrid)) ; López-Vacas, Rocío (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Prado-Vázquez, Guillermo (Biomedica Molecular Medicine SL, C/Faraday 7, 28049, Madrid, Spain) ; López-Camacho, Elena (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Zapater-Moros, Andrea (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Heredia Soto, Victoria (Hospital Universitario La Paz (Madrid)) ; Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ; Conill, Carles (Hospital Clínic i Provincial de Barcelona) ; García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ; Heath, Karen E. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Ramos-Ruiz, Ricardo (Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Llorens, Carlos (Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain) ; Campos-Barros, Ángel (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Gámez-Pozo, Angelo (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Feliu, Jaime (Universidad Autónoma de Madrid) ; Vara, Juan Ángel Fresno (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the standard of care, with no therapeutic advances achieved over the past three decades. Thus, a deeper molecular characterization of this disease is still necessary. [...]
2020 - 10.1016/j.tranon.2020.100778
Translational Oncology, Vol. 13 (may 2020)  
7.
11 p, 912.9 KB Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis / Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron) ; Sevilla, Isabel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Antón Aparicio, Luís (Complejo Hospitalario Universitario de A Coruña) ; Jiménez Fonseca, Paula (Hospital Universitario Central de Asturias) ; Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ; Reina, Juan José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Manzano, José Luís (Hospital Universitari Vall d'Hebron) ; Alonso Lájara, Juan Domingo (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ; Barriuso, Jorge (Hospital Universitario La Paz (Madrid)) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Medina, Javier (Complejo Hospitalario de Toledo) ; López, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Segura, Ángel (Hospital Universitari i Politècnic La Fe de València) ; Carrera, Sergio (Hospital Universitario de Cruces (Barakaldo, País Basc)) ; Crespo, Guillermo (Hospital Universitario de Burgos) ; Fuster, José (Hospital Universitari Son Dureta (Palma de Mallorca, Balears)) ; Munarriz, Javier (Consorci Hospitalari Provincial de Castelló) ; García Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Universitat Autònoma de Barcelona
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). [...]
2015 - 10.1186/s12885-015-1512-6
BMC Cancer, Vol. 15 (july 2015)  

Vegeu també: autors amb noms similars
3 García-Alfonso, P.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.